Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Microbot Medical (NASDAQ: MBOT) has announced the appointment of Professor Gerry O’Sullivan to its Scientific Advisory Board, enhancing its EU presence as it prepares for human clinical trials of the LIBERTY® Robotic System. With over 25 years of experience in interventional radiology, Professor O’Sullivan brings expertise in venous disease treatments. His involvement is expected to bolster innovation and execution of commercialization strategies. This comes amid increasing global interest in the LIBERTY system, designed to address the needs of interventional radiologists.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) with the appointment of Professor Mark W. Little, a distinguished academic leader from the UK. Professor Little will collaborate with other experts to enhance the regulatory and commercialization efforts for the LIBERTY Robotic System, the first single-use endovascular robotic device. Having significant experience in interventional radiology, he has previously participated in studies on the LIBERTY system and expressed confidence in its potential impact on the market. This addition signals a strengthening of the company’s clinical expertise and reinforces its strategic goals.